KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today initiation of dosing in BLAST-AHF, the Company’s randomized, multi-center Phase 2b trial of TRV027 in patients with acute heart failure (AHF). TRV027 is a novel beta-arrestin biased ligand of the angiotensin II type 1 receptor that is being developed as a first-line intravenous treatment in combination with standard diuretic therapy for AHF patients. Trevena has granted Forest Laboratories (NYSE:FRX) an exclusive option to license TRV027 under the companies’ May 2013 Option and Licensing Agreements.
Help employers find you! Check out all the jobs and post your resume.
